The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1739
October 13, 2025
View Complete Issue         Table of Contents 2019 
Semaglutide (Wegovy) for MASH
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Semaglutide (Wegovy) for MASH
October 13, 2025 (Issue: 1739)
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has received accelerated approval from the FDA for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH; previously known...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Semaglutide (Wegovy) for MASH
Article code: 1739a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.